Ultragenyx Pharmaceutical (RARE) Preferred Stock Liabilities (2013)
Ultragenyx Pharmaceutical (RARE) reported Preferred Stock Liabilities of $51.0 million for Q4 2013.
Ultragenyx Pharmaceutical (RARE) has 1 years of Preferred Stock Liabilities data on file, last reported at $51.0 million in Q4 2013.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $51.0 million in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $51.0 million (changed N/A YoY) and the FY2013 annual result came in at $51.0 million, up 36.16% from the prior year.
- Preferred Stock Liabilities held at $51.0 million in Q4 2013 per RARE's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $51.0 million in Q4 2013 and bottomed at $51.0 million in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 51.00 Mn |